Zia (on behalf of Charles Duncan)'s questions to Cytokinetics Inc (CYTK) leadership • Q3 2024
Question
Zia from Cantor Fitzgerald asked about the competitive positioning of omecamtiv mecarbil in the heart failure market, given ongoing developments, as the company prepares to initiate the COMET-HF trial.
Answer
Fady Malik, EVP of R&D, Stuart Kupfer, SVP & CMO, and Andrew Callos, EVP & CCO, collectively addressed the question. They highlighted that omecamtiv targets a high-risk HFrEF population (EF <30%) with few effective options, a unique mechanism of action, a strong economic argument, and significant commercial synergies with the planned aficamten infrastructure.